Neumora Therapeutics EPS NMRA

Diluted earnings per share by quarter and over the last twelve months, from 2022.

Neumora Therapeutics' earnings per share was −$1.23 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.23.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.23	n/a	−$1.23
Q1 FY26	Mar 31, 2026	−$0.30	n/a	−$1.33
Q4 FY25	Dec 31, 2025	−$0.35	n/a	−$1.45
Q3 FY25	Sep 30, 2025	−$0.35	n/a	−$1.47
Q2 FY25	Jun 30, 2025	−$0.33	n/a	−$1.57
Q1 FY25	Mar 31, 2025	−$0.42	n/a	−$1.61
Q4 FY24	Dec 31, 2024	−$0.37	n/a	−$1.53
Q3 FY24	Sep 30, 2024	−$0.45	n/a	−$1.87
Q2 FY24	Jun 30, 2024	−$0.37	n/a	−$2.56
Q1 FY24	Mar 31, 2024	−$0.34	n/a	−$3.47
Q4 FY23	Dec 31, 2023	−$0.71	n/a	−$4.35
Q3 FY23	Sep 30, 2023	−$1.14	n/a	−$4.63

Companies in Healthcare nearest Neumora Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
NMRANeumora Therapeutics	−$1.23
LFVNLifevantage	$0.40	−46% a year
SPROSpero Therapeutics	$0.11
APTAlpha Pro Tech	$0.41	+24% a year
ICCCImmucell	$0.08	−58% a year
KEQUKewaunee Scientific	$2.76	−33% a year
ATNMActinium Pharmaceuticals	$0.36
NEPHNephros	$0.16	+33% a year
PDEXPro DEX	$4.11	+52% a year
PLXProtalix BioTherapeutics	$0.23	+283% a year
NATRNatures Sunshine Products	$1.01	+36% a year
Peer median	$0.38